Compare EQPT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQPT | PCVX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | 8206 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.1B |
| IPO Year | N/A | 2020 |
| Metric | EQPT | PCVX |
|---|---|---|
| Price | $20.11 | $58.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $40.50 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 03-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.16 | N/A |
| Revenue Next Year | $24.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.80 | $28.09 |
| 52 Week High | $35.50 | $65.00 |
| Indicator | EQPT | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 32.57 | 56.87 |
| Support Level | $19.61 | $42.30 |
| Resistance Level | $34.95 | $58.95 |
| Average True Range (ATR) | 1.73 | 2.13 |
| MACD | -0.05 | 0.28 |
| Stochastic Oscillator | 20.36 | 81.15 |
EquipmentShare.com Inc is a vertically integrated platform that combines proprietary technology, a connected equipment fleet, and a nationwide footprint to serve the construction industry. The company operates its business through the following reportable segments: Equipment Rental and Services Operations, comprised of recurring activity performed at full-service branch locations, such as equipment rentals and related services, and sales of parts, supplies, and maintenance services to construction contractors and others. Equipment Sales, sales of new or used equipment made at any of the branch locations and dealership sites, including equipment sales to participants in the OWN Program.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.